Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood. 2007 Nov 15;110(10):3552-6. Epub 2007 Aug 20.

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

Author information

  • 1Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD 20892, USA. aklion@nih.gov

Abstract

PMID:
17709602
[PubMed - indexed for MEDLINE]
PMCID:
PMC2077306
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk